• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
July 2, 2025 01:03 PM EDTUpdated 01:28 PM
Pharma
Law

Ab­b­Vie los­es bid to block Ten­nessee's 340B con­tract phar­ma­cy law

Alexis Kramer

Deputy Editor

Ab­b­Vie failed to per­suade a fed­er­al judge to block a re­cent Ten­nessee law that aims to reg­u­late drug­mak­er dis­count poli­cies un­der the fed­er­al 340B pro­gram …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

more like this

  • So­ri­ot mulls mov­ing As­traZeneca stock list­ing to the US — re­port July 2, 2025
  • Fed­er­al judge or­ders block on parts of HHS re­or­ga­ni­za­tion plan af­ter states sue July 1, 2025
  • PBM re­forms fail to make the cut as Sen­ate pass­es Trump’s mega­bill July 1, 2025
TRENDING NOW

Chi­na’s rise splits US biotech in­vestors: Cash in, or counter? 

FDA re­view­ers ad­vised broad la­bel for Mod­er­na’s next-gen Covid vac­cine. Prasad over­ruled them

Bris­tol My­er­s' Chi­na part­ner touts Phase 3 suc­cess for EGFRx­HER3 bis­pe­cif­ic ADC

Ab­b­Vie cans oral ul­cer­a­tive col­i­tis drug from Lan­dos buy­out

Af­ter de­lay, Re­gen­eron wins US ap­proval of bis­pe­cif­ic in mul­ti­ple myelo­ma

CDC ex­pands RSV vac­cine rec­om­men­da­tions, sid­ing with pre­vi­ous pan­el of agency ad­vi­sors

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times